$72.82
10.07% yesterday
Nasdaq, Oct 02, 10:17 pm CET
ISIN
CH0334081137
Symbol
CRSP

CRISPR Therapeutics AG Stock News

Neutral
GlobeNewsWire
2 days ago
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress, taking place October 7-10, 2025. The presenta...
Positive
The Motley Fool
2 days ago
You don't have to invest a fortune to get involved in an industry that could offer your portfolio growth along with safety. I'm talking about the field of healthcare, specifically companies that develop therapeutics.
Neutral
The Motley Fool
3 days ago
Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make informed investment choices. Not every company can generate the kind of returns over the long run that will help you achieve that goal -- in fact, most probably won't.
Neutral
Seeking Alpha
15 days ago
Crispr Therapeutics AG remains undervalued despite recent stock volatility and slow Casgevy commercial uptake, with long-term potential intact. Casgevy's strong clinical data and broad approvals are tempered by complex administration and high costs, but demand remains robust and efficiency is improving. CRSP's pipeline—including allogeneic CAR-T, in vivo gene editing, and diabetes programs—offe...
Positive
The Motley Fool
22 days ago
Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase her bet -- at a great price.
Neutral
GlobeNewsWire
23 days ago
ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that a late-breaking oral presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 in vivo gene editing therapy, CTX310™, targeting ang...
Positive
Barrons
24 days ago
Last week, the SPDR S&P Biotech ETF surged 6%.
Neutral
Seeking Alpha
24 days ago
CRISPR Therapeutics AG (NASDAQ:CRSP ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today